Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius AP-32 + lactobacillus reuteri GL-104
- Development stage
- Preclinical
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PRONULIFE GlukoSolu is a probiotic combination developed by Glac Biotech Co., Ltd., consisting of two specific bacterial strains: *Lactobacillus salivarius* AP-32 and *Lactobacillus reuteri* GL-104. This biologic therapy is designed for the management of type 2 diabetes mellitus (T2DM). The mechanism of action involves the downregulation of monosaccharide transporters in the intestinal tract, specifically sodium-glucose co-transporter 1 (SGLT1) and glucose transporter 5 (GLUT5). By modulating these transporters, the combination helps reduce glucose absorption, thereby lowering fasting blood glucose levels and improving glucose tolerance. Preclinical studies in diabetic models have also demonstrated improvements in blood lipid profiles and protective effects on β-cells, liver, and kidney functions.
- Brand names
- PRONULIFE GlukoSolu
- Other names
- Lactobacillus salivarius AP-32 + Lactobacillus reuteri GL-104
02
Targets
SLC5A1 (Sodium Glucose Cotransporter 1)GLUT5 (Glucose transporter 5)
Beyond the preview
Go deeper on lactobacillus salivarius AP-32 + lactobacillus reuteri GL-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius AP-32 + lactobacillus reuteri GL-104.